OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
2.050
+0.010 (0.49%)
At close: Jan 30, 2026, 4:00 PM EST
2.041
-0.009 (-0.44%)
After-hours: Jan 30, 2026, 7:56 PM EST
OKYO Pharma Employees
OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,153,335
Market Cap
77.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 4 | 1 | 33.33% |
| Mar 31, 2024 | 3 | -5 | -62.50% |
| Mar 31, 2023 | 8 | 1 | 14.29% |
| Mar 31, 2022 | 7 | 1 | 16.67% |
| Mar 31, 2021 | 6 | 2 | 50.00% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pliant Therapeutics | 171 |
| Immunic | 90 |
| PolyPid | 60 |
| Mereo BioPharma Group | 36 |
| Gain Therapeutics | 25 |
| Entera Bio | 22 |
| Atossa Therapeutics | 15 |
| Annovis Bio | 15 |
OKYO News
- 19 hours ago - OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting - GlobeNewsWire
- 2 days ago - OKYO Pharma Announces Successful Type C Meeting with the FDA - GlobeNewsWire
- 8 days ago - FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain - GlobeNewsWire
- 6 weeks ago - OKYO Pharma to Ring the Opening Bell at Nasdaq - GlobeNewsWire
- 6 weeks ago - OKYO Pharma Announces Chairman and Founder Acquires Shares - GlobeNewsWire
- 2 months ago - OKYO Pharma to Present at OIS XV in San Diego - GlobeNewsWire
- 4 months ago - OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain - GlobeNewsWire
- 7 months ago - OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire